Overview

COX‑2 inhibitors are a class of medicines developed to relieve pain and reduce inflammation while minimizing certain gastrointestinal side effects associated with older nonsteroidal anti-inflammatory drugs (NSAIDs). They target a specific form of the cyclooxygenase enzyme system: COX‑2. The term analgesic is commonly used to describe their pain-relieving role, and they act by reducing production of inflammatory mediators.

Mechanism and characteristics

Cyclooxygenase (or COX) enzymes convert arachidonic acid into prostaglandins and related compounds. Two main isoforms are COX‑1 and COX‑2: COX‑1 is constitutively active in many tissues, while COX‑2 is inducible and strongly associated with sites of inflammation and pain. By selectively inhibiting COX‑2, these drugs lower prostaglandin levels linked to swelling and pain without blocking the protective COX‑1 functions in the stomach lining and platelets to the same extent.

Clinical uses and examples

COX‑2 inhibitors have been used for chronic conditions such as osteoarthritis and rheumatoid arthritis, as well as for acute pain and primary dysmenorrhea. Some agents were studied experimentally for roles in oncology and certain neuropsychiatric conditions such as depression and schizophrenia, but these uses remain investigational. Examples of COX‑2 selective drugs include:

  • celecoxib (commonly still prescribed)
  • rofecoxib (formerly marketed)
  • valdecoxib and others withdrawn in some regions

Safety, warnings and regulatory history

While selective inhibition of COX‑2 tends to reduce the incidence of gastric bleeding associated with COX‑1 inhibition, it does not eliminate all risks. COX‑1 contributes to maintenance of renal blood flow, so renal function can still be affected; kidneys are a particular concern when using these agents (kidney). Traditional gastrointestinal bleeding risks such as bleeding and stomach irritation (stomach) are reduced but not absent. Importantly, clinical studies linked some COX‑2 inhibitors to an increased incidence of major cardiovascular events, including heart attack and stroke, which led to market withdrawals and stronger labeling.

Practical considerations and distinctions

Because of these safety considerations, COX‑2 inhibitors are often dispensed only with a prescription and require individual risk assessment. They differ from nonselective NSAIDs in selectivity (degree of COX‑2 vs COX‑1 inhibition) and in their balance of gastrointestinal versus cardiovascular risk. When prescribing or using these medicines, clinicians weigh the benefits for pain and inflammation against potential renal, cardiovascular, and other adverse effects.

Notable facts

Regulatory actions in the early 2000s changed how COX‑2 inhibitors are perceived and used. Withdrawn drugs prompted more rigorous post‑marketing surveillance and influenced the design of later studies. Choice of anti-inflammatory therapy remains tailored: some patients benefit from COX‑2 selectivity, others are better served by alternatives. For additional summaries and definitions see entries on analgesic mechanisms and the COX enzyme family (COX), and consult professional guidance for clinical decision making.